RegenxbioRGNX
RGNX
About: Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Employees: 344
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 5 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
25% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 51
15% more first-time investments, than exits
New positions opened: 31 | Existing positions closed: 27
2% more funds holding
Funds holding: 182 [Q2] → 186 (+4) [Q3]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q2] → 3 (+0) [Q3]
2.92% less ownership
Funds ownership: 91.28% [Q2] → 88.36% (-2.92%) [Q3]
13% less capital invested
Capital invested by funds: $526M [Q2] → $458M (-$67.9M) [Q3]
77% less call options, than puts
Call options by funds: $1.5M | Put options by funds: $6.66M
Research analyst outlook
5 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$18
136%
upside
Avg. target
$33
328%
upside
High target
$52
582%
upside
5 analyst ratings
5 positive
100%
0 neutral
0%
0 negative
0%
RBC Capital Luca Issi 27% 1-year accuracy 15 / 56 met price target | 359%upside $35 | Outperform Reiterated | 11 Dec 2024 |
HC Wainwright & Co. Yi Chen 39% 1-year accuracy 60 / 154 met price target | 372%upside $36 | Buy Maintained | 21 Nov 2024 |
Chardan Capital Daniil Gataulin 25% 1-year accuracy 8 / 32 met price target | 582%upside $52 | Buy Maintained | 20 Nov 2024 |
Morgan Stanley Judah Frommer 38% 1-year accuracy 3 / 8 met price target | 189%upside $22 | Overweight Assumed | 15 Nov 2024 |
Raymond James Danielle Brill 64% 1-year accuracy 9 / 14 met price target | 136%upside $18 | Outperform Reinstated | 10 Oct 2024 |
Financial journalist opinion
Neutral
PRNewsWire
2 weeks ago
Apollo Global Management and Workday Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
NEW YORK , Dec. 6, 2024 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 23, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range.
Neutral
PRNewsWire
1 month ago
REGENXBIO INITIATES PIVOTAL PHASE OF AFFINITY DUCHENNE® TRIAL OF RGX-202 GENE THERAPY AND REPORTS POSITIVE FUNCTIONAL DATA
Alignment achieved with FDA on AFFINITY DUCHENNE® pivotal program and access to accelerated approval; BLA expected in 2026 Pivotal trial of RGX-202 is enrolling ambulatory patients aged 1 and above with first patient dosed Phase I/II data show RGX-202 recipients exceeding external natural history and established benchmarks for clinical outcomes Functional improvements seen in all patients treated with dose level 1 and dose level 2 at 12 and 9 months respectively New biomarker data confirms consistent robust expression of differentiated RGX-202 microdystrophin in the muscle Favorable safety profile observed at both dose levels; no serious adverse events or AEs of special interest Webcast to be held at 8:00 a.m. today ROCKVILLE, Md.
Neutral
PRNewsWire
1 month ago
REGENXBIO to Host Webcast Discussing Pivotal Program and First Functional Data from the AFFINITY DUCHENNE® Trial of RGX-202
- Event will feature Aravindhan Veerapandiyan, M.D., principal investigator of the AFFINITY DUCHENNE® trial and Michael Kelly, PhD, Chief Scientific Officer of CureDuchenne ROCKVILLE, Md.
Neutral
Seeking Alpha
1 month ago
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
REGENXBIO Inc. (RGNX) Q3 2024 Earnings Call Transcript
Negative
Zacks Investment Research
1 month ago
Regenxbio (RGNX) Reports Q3 Loss, Tops Revenue Estimates
Regenxbio (RGNX) came out with a quarterly loss of $1.17 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.41 per share a year ago.
Neutral
PRNewsWire
1 month ago
REGENXBIO Reports Third Quarter 2024 Financial Results and Recent Operational Updates
Advancement in Phase I/II AFFINITY DUCHENNE® trial of RGX-202 for Duchenne Muscular Dystrophy; pivotal trial initiation and first functional data expected this month BLA submission for RGX-121 initiated and expected to complete in Q1 2025 Positive Phase II data support bilateral administration of subretinal ABBV-RGX-314; data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile End-of-Phase II meeting for ABBV-RGX-314 in diabetic retinopathy accelerated to Q4 2024 to support global pivotal program initiation in H1 2025 Conference call today at 4:30 p.m. ET ROCKVILLE, Md.
Neutral
PRNewsWire
1 month ago
REGENXBIO to Participate in Upcoming Investor Conferences
ROCKVILLE, Md. , Nov. 4, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences: UBS Global Healthcare Conference Fireside Chat: Wednesday, November 13 at 12:30 p.m.
Positive
Seeking Alpha
1 month ago
REGENXBIO: With Additional MPS II Data, Program Advancement Remains On Track
Positive updated long-term results from phase I/II/III CAMPSITE study using RGX-121 for the treatment of patients with MPS II. Rolling BLA submission of RGX-121 for the treatment of patients with MPS II expected any day now in Q4 of 2024. The global Hunter Syndrome treatment market is expected to reach $1.78 billion by 2030.
Neutral
PRNewsWire
1 month ago
REGENXBIO to Host Conference Call on November 6 to Discuss Third Quarter 2024 Financial Results and Recent Operational Highlights
ROCKVILLE, Md. , Oct. 30, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that it will host a conference call on Wednesday, November 6, at 4:30 p.m.
Neutral
PRNewsWire
2 months ago
REGENXBIO Presents Positive Data from the Phase II Study of Subretinal ABBV-RGX-314 in Patients with Bilateral Wet AMD at AAO 2024
97% reduction in treatment burden at nine months after treatment with ABBV-RGX-314 Data consistent with that from multiple previous studies demonstrating favorable safety and efficacy profile Well tolerated with zero cases of intraocular inflammation in a setting of no prophylactic steroids Data highlight the potential of ABBV-RGX-314 to treat both eyes in wet AMD ROCKVILLE, Md. , Oct. 21, 2024 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced positive data from the Phase II fellow eye sub-study evaluating the subretinal delivery of ABBV-RGX-314 in patients with bilateral wet age-related macular degeneration (wet AMD).
Charts implemented using Lightweight Charts™